Document is current
Any future updates will be listed below
-
Authors
Song, Ling
Wang, Xiaoxu
Sun, Jingfang
Hu, Xinyu
Li, Haiyan
Hu, Pei
Liu, Dongyang https://orcid.org/0000-0001-6446-0127
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81903717)
Bill and Melinda Gates Foundation (INV-007625)
Peking University Third Hospital (BYSYFY2021006)
- License Information
-
More Information
Article History
Accepted: 29 December 2022
First Online: 18 February 2023
Declarations
:
: The study was supported by the National Natural Science Foundation of China (No. 81903717), The Bill & Melinda Gates Foundation, Grant/Award Number: INV-007625, and The Peking University Third Hospital Clinical Project, Grant/Award Number: BYSYFY2021006.
: Jingfang Sun and Xinyu Hu are employees in Huisheng Bio-pharmaceutical (Jilin) Ltd., the company owing janagliflozin. Ling Song, Xiaoxu Wang, Haiyan Li, Pei Hu and Dongyang Liu, declare no conflicts of interest that might be relevant to the contents of this manuscript.
: The data used in this study were collected in line with the principles of the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees for each study from which data were used in this work.
: All data generated or analysed during this study are included in this published article (and its supplementary information files).
: Dr. Ling Song, Dongyang Liu and Pei Hu designed the study, Dr. Ling Song, Xiaoxu Wang conducted the modeling and simulation work. Dr. Jingfang Sun and Xinyu Hu offered the preclinical and clinical raw data. Dr.Haiyan Li gave the writing suggestion for this article.
: Not applicable.
: Not applicable.
: Not applicable.
